A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

Sponsor
Abbott
Study ID
NCT00233571
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in patients with rheumatoid arthritis

Key Dates

Start date
Jun 30, 2000
Status verified
Nov 2011
Primary completion
Jun 30, 2006
Completion
Jun 30, 2006

Study Design

Enrollment
796 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Adalimumab 40mg subcutaneous (SC) every other week (EOW)
    Adalimumab 40mg subcutaneous (SC) every other week (EOW)

Primary Outcome Measure

Clinical response indicators [ Time Frame: 5 years ]

Related Studies